An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-thanexpected sales for the third quarter, even as supply of both medicines have largely recovered from widespread shortages in the U.S. The reason, according to the company, is not an issue of demand or supply. Eli Lilly instead blamed disappointing sales on drug wholesalers cutting inventory o ...